10 Best Life Sciences Stocks to Buy According to Hedge Funds

Page 8 of 10

3. IQVIA Holdings (NYSE:IQV)

Number of Hedge Fund Holders: 61

IQVIA Holdings (NYSE:IQV) is one of the 10 best life sciences stocks to buy according to hedge funds.

On February 19, Jailendra Singh from Truist Financial reiterated his Buy rating for IQVIA Holdings (NYSE:IQV). He lowered the price target on the stock from $290 to $274, which still offers an impressive upside potential of more than 65% despite the revision.

Singh’s price target revision followed the company’s fourth-quarter results, prompting the firm to adjust its model. These adjustments incorporate a re-segmentation for the company, as well as a reduction in the forward EBITDA multiple projections, from 14x to 13x. They also take into account the AI-related uncertainties in the near-term.

On February 17, Charles Rhyee from TD Cowen reaffirmed his Hold rating on IQVIA Holdings (NYSE:IQV) and lowered the price target from $245 to $174. The firm revised its model following the fourth quarter announcements. He acknowledged that while AI poses potential risks to the segment, these are likely to emerge over the long-term. But for now, the impact on CROs remains uncertain.

IQVIA Holdings (NYSE:IQV) delivers clinical research services, advanced analytics, commercial insights, and market intelligence to healthcare and life sciences segments worldwide. The company covers end-to-end clinical trials, offering protocol design, site selection, recruitment, and data analysis. It also offers cloud-based commercial solutions such as CRM, contract sales, and analytics.

Page 8 of 10